Eurofarma Signs an Exclusive Development and Commercialization Agreement with NLS-1 Pharma for its Nalazol Therapy

 Eurofarma Signs an Exclusive Development and Commercialization Agreement with NLS-1 Pharma for its Nalazol Therapy

Eurofarma Signs an Exclusive Development and Commercialization Agreement with NLS-1 Pharma for its Nalazol Therapy

Shots:

  • Eurofarma to get exclusive license rights to develop and commercialize NLS-1 Pharma’s Nalazol Therapy in Central & South America and to take care of its regulatory approval
  • In 2002, Mazindol was recalled from the US market based on its commercial sales (low sales). NLS-1 Pharma’s Mazindol control released formulation, Nalazol is expected to be marketed in H1’20
  • Nolazol (mazindol, control release) is a non-amphetamine targeted as a C-4 treament for ADHD and is evaluated in P-II study and has shown efficacious results with no new safety signals

TClick here to read full press release/ article | Ref: Business Wire | Image : Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post